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SUMMARY
Increasing numbers of non-travel-associated hepatitis E virus (HEV) infections have been reported
in Europe in recent years. Our objective was to review the evidence on risk factors and transmission
routes of autochthonous HEV infection and hepatitis E in Europe in order to develop
recommendations for future research, prevention and control. A systematic literature review was
performed to identify all primary reports and studies published during 1998–2008 on hepatitis E in
humans and animals in Europe by searching Pubmed, reference lists of major articles and
international conference proceedings. Each of the 106 included studies was categorized into one of
three evidence levels (EL) based on study design and diagnostic methodology. The evidence was
generally weak (73 were assigned to EL1, two to both EL1 and EL2, and 30 to EL2), further
compounded by the use of poorly validated serological assays in some studies. Only one case-
control study was assigned to EL3. Persons with autochthonous hepatitis E infection were on
average older than the general population and predominantly male. There was no evidence for one
main transmission route of HEV infection or risk factor for hepatitis E. However, zoonotic
transmission seemed likely and person-to-person transmission too inefficient to cause clinical
disease. Multiple routes of transmission probably exist and should be further investigated through
analytical studies and reliable diagnostic kits. Based on current evidence that points to zoonotic
transmission from pigs, thorough cooking of all porcine products, prevention of cross-
contamination in the kitchen and improved education for occupationally exposed people (e.g. pig
farmers, veterinarians and sewage workers) may help prevent HEV infection. Although evidence
for parenteral transmission is limited, it is recommended that a risk assessment is undertaken.
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INTRODUCTION
Hepatitis E virus (HEV) infection is a major cause of
epidemic and acute sporadic hepatitis in many areas
of Asia, Africa and Mexico [1], where HEV is
considered hyper-endemic. Traditionally, industrial-
ized countries were considered non-endemic, with
most HEV infections in these regions being sporadic
and considered to be imported. However, in recent
years, enhanced surveillance has detected an increas-
ing number of non-travel-associated HEV infections,
especially in Europe and Japan [2]. In addition, un-
expectedly high anti-HEV immunoglobulin G (IgG)
seroprevalence among the general population has
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been reported from some industrialized countries,
although the rates varied considerably between re-
ports, ranging from 2.3 to 33% [3–9].
HEV is a non-enveloped, ribonucleic acid (RNA)
virus. Its genome is single-stranded, about 7.2 kb in
length and contains three open reading frames. HEV
is classified in the family Hepeviridae and consists
of genotypes (gt) 1–4 that infect humans and other
mammals, and a group of avian HEV strains that
probably constitute a separate genus [10]. Of interest,
the majority of HEV strains from human cases ac-
quired in industrialized countries are different gen-
etically to those isolated from cases in, or imported
from, hyper-endemic countries. This geographical
difference in genotype distribution contributed to the
hypothesis that HEV gt1 and gt2 lead to hepatitis E
with a different clinico-epidemiological entity com-
pared to hepatitis E caused by gt3 and gt4 viruses [11,
12] (Fig. 1). In contrast to hyper-endemic regions
where HEV gt1 is predominately found during large
waterborne outbreaks, autochthonous infections in
Europe are usually sporadic and related to gt3. The
higher standard of hygienic conditions in industrial-
ized countries makes the waterborne route of HEV
transmission unlikely in these regions and might ex-
plain the rare occurrence of gt1 infections among
autochthonous cases. Thus, it is hypothesized that gt3
is linked to different sources and routes of infection
than gt1.
As early as 1990, Balayan and co-workers postu-
lated that HEV could be a zoonosis since a human
HEV strain was found to be capable of infecting
domestic pigs [13]. In 1997, HEV gt3 strains were
detected in swine in the USA [14]. HEV gt3 and gt4
have since been found to be endemic in pig herds
worldwide [15, 16]. Both genotypes, whether from
pigs or humans, have been shown to be transmissible
to non-human primates and a range of other animal
species [17, 18]. Very close homology (>90%) has
been found between HEV gt3 nucleotide sequences
from pigs, wild boar and humans, suggestive of cross-
species transmission [6, 19]. As HEV gt3 spreads
easily in pig herds but poorly in human communities
it has been postulated that humans are not the main
host or reservoir [20].
The diagnosis of a HEV infection is mainly de-
pendent on serology. In general, a positive result
for anti-HEV immunoglobulin M (IgM) antibodies,
or a rise in anti-HEV IgG titre, is indicative of an
acute infection. Recent studies have shown that
the use of commercially available serological tests
(which are mainly based on HEV gt1 antigens) in
HEV gt3-endemic regions need further confirmation
[6, 21]. Moreover, a comparison of five serological
tests showed that the agreement between the tests
was moderate at best (kappa y0.5) [22]. A couple
of IgG enzyme-linked immunosorbent assay (ELISA)
commercial kits were withdrawn from the market
or replaced by new tests by the manufacturer due
to recognition of a high proportions of false-negative
results [22, 23]. There are also many reports on the
detection of anti-HEV antibodies in serum samples
from different animals [17] but these results are
often obtained using tests that are developed and
evaluated for detecting anti-HEV antibodies in hu-
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Fig. 1. Summary of epidemiology and transmission of mammalian HEV.
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The reliability of these results is therefore question-
able.
Detection of a part of the virus, for example HEV
RNA, in serum or faecal samples, instead of detection
of an immune response against antigens of a virus,
is more definite proof for HEV infection. Several re-
ports state that the viraemic phase of HEV in humans
is, in general, short and that the virus may disappear
from peripheral blood at the height of the disease
(reviewed by Jameel [24]). Nevertheless, HEV RNA
might be detectable in faecal samples for a longer
period of time [25] and recent prolonged infection
and shedding has been reported for some immuno-
compromised patients [26].
The clinical presentation of hepatitis E in humans
is indistinguishable from hepatitis A. Commonly re-
ported symptoms include jaundice, anorexia, abdomi-
nal pain and hepatomegaly accompanied by fever,
nausea and vomiting [27]. Hepatitis E is usually self-
limiting but very recently chronic infections have been
described in organ transplant recipients in France
[28, 29] and The Netherlands [26]. Fulminant and
even fatal hepatitis E caused by gt3 have been re-
ported in Japan [30] and in Europe [31–35], often in
older males with underlying chronic liver disease. In
contrast, in hyper-endemic gt1 and gt2 areas, preg-
nant women are at higher risk for severe disease and
death [36, 37]. This feature has not yet been reported
for HEV gt3 infections.
In Europe, acute HEV infection is diagnosed in
5–15% of patients with acute hepatitis for whom
hepatitis A, B and C has been ruled out [6, 38–41].
Requests for HEV testing in patients without travel
history continue to be infrequent and consequently
the actual number of hepatitis E cases is under-
estimated.
In industrialized countries, little is known about
possible sources and transmission routes for en-
demic human HEV infections. Research is hindered
because outbreaks are rarely detected, many infec-
tions remain asymptomatic and there is a long
and variable incubation period. Narrative, non-
systematic reviews have commented on the zoonotic
potential and other transmission routes of HEV
[11, 42]. However, none have documented a systematic
review process or specifically focused on Europe. Our
objectives were to determine risk factors for HEV
infection and disease and the likely routes of HEV
transmission in Europe. We systematically reviewed
the scientific literature to give an overview of the
evidence available from the last ten years and make
recommendations for future research, and prevention
and control.
METHODS
Literature search and data extraction
A systematic review of the literature was performed
to identify all primary reports and studies that have
been published between January 1998 and September
2008, conducted on: (i) HEV infection or anti-HEV
antibody prevalence in humans, or (ii) HEV or anti-
HEV antibody prevalence in food, animals or the
environment. The primary objective was to review
and report on the current knowledge and evidence
that exists on risk factors for hepatitis E and the most
likely routes of HEV transmission in Europe. Thus,
the review was limited to the occurrence of HEV
infection and disease in Europe, and three report
categories were included: (i) original studies published
in peer-reviewed scientific journals, (ii) abstracts in
conference proceedings, and (iii) correspondence with
scientific experts.
For the first category, an electronic search of
the United States National Library of Medicine and
the National Institutes of Health Medical Database
(Pubmed) from its inception was conducted in
September 2008. Search words used were: (‘HEV’ or
‘hepatitis E’) and (‘zoonosis ’ or ‘zoonotic ’ or ‘epi-
demiology’ or ‘ food’ or ‘environment’ or ‘animal’ or
‘pig ’ or ‘meat ’ or ‘rodent’ or ‘ indigenous’ or ‘auto-
chthonous’ or ‘ industrialized’). Articles from 1998
onwards were picked out manually. To verify the
search, reference lists of the five most recent literature
reviews and five most cited primary articles investi-
gating the zoonotic potential of hepatitis E were
hand-searched and relevant citations were added to
the database. For the second category, a hand-search
included eight international conference proceedings
held between 2006 and 2008: International Con-
ference on Emerging Infectious Diseases (ICEID),
Med-Vet-Net annual scientific meetings, International
Meeting on Emerging Diseases and Surveillance
(IMED) and International Congress on Infectious
Diseases (ICID). Finally, when a published study
could not be located, we contacted topic-related
scientists of relevant conference abstracts to gather
more detailed information.
Abstracts were examined to determine if the in-
clusion criteria were met. A relevance tool was then
applied to the selected reports : (1) countries are
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contained entirely within continental Europe
(i.e. excluding Turkey and the Russian Federation);
(2) abstract is in English, French, German or Dutch;
(3) diagnosis of hepatitis E or HEV infection was
laboratory-confirmed using recognized tests ; (4) re-
port has relevance to transmission of, or risk factors
for, autochthonous HEV infection (including reports
with isolation of HEV gt3). If one of the four criteria
was not met, the report was excluded.
For each report or study included, the following
information was extracted (as applicable to study) :
type of study, location (country and setting), study
population (number of cases, patients or risk groups,
etc.), demographics (age and sex), laboratory tests
utilized, positivity rates of humans and animals tested
by serological tests and for RNA, HEV genotype, risk
factors questioned about, and risk factors found.
Assessment of level of evidence and critical appraisal
Each identified study was categorized to an evidence
level (EL) regarding the route of transmission of HEV
in Europe, taking both study design and diagnostic
methodology into account and using the risk assess-
ment template developed by Palmer et al. [43] as
follows:
Evidence level 1
’ Single human case report confirmed by detection
of anti-HEV IgM or HEV RNA, or,
’ human hepatitis E case series diagnosed by detec-
tion of anti-HEV IgM or HEV RNA without
specific exposures by subgroup, or,
’ serosurveys carried out on acute non-A–C hepatitis
patients (without comparison of risk groups) with
a proportion of cases confirmed by detection of
anti-HEV IgM or HEV RNA, or,
’ animal or environmental studies finding HEV gt3
RNA in samples with <100% nucleotide sequence
relatedness to human HEV.
Evidence level 2
’ Enhanced surveillance with hepatitis E case series
confirmed by detection of anti-HEV IgM or HEV
RNA and cases with specific exposures by sub-
group, or
’ serosurvey data comparing risk groups vs. non-risk
groups. The limitations of the diagnostic kits used
in some of these studies were taken into account by
limiting data interpretation to comparative data
and consideration not being given to the absolute
levels of seroprevalence found.
Evidence level 3
’ Analytical epidemiological study (case-control
study or cohort study), or
’ single human case reports with 100% RNA se-
quence identity between source and human HEV.
RESULTS
Of 1884 de-duplicated citations published between
1998 and 2008, 110 reports or studies were relevant
primary papers or conference proceedings that were
suitable for inclusion (Table 1).
Identification of relevant studies by evidence level
Evidence level 1
For HEV in humans, 37 reports pertaining to HEV
reservoir and transmission routes can be divided into
single case reports (n=16) or case-series (n=18) with
the remaining three studies adding molecular se-
quencing results (Table 2). Even though these reports
provide only a weak level of evidence to evaluate
risk factors for infection or disease, the majority do
provide descriptive epidemiological information and
Table 1. Inclusion and exclusion criteria used for
this review and number of reports identified
Criteria n
Potential relevant reports identified by
the search of Pubmed
1884
Application of inclusion criteria
(i) Published after 1998 (x750) 1134
(ii) Relevant study type (x580) 554
Application of exclusion criteria
(i) Acquired infection outside Europe
(x444)
110
(ii) Publication language not
English/French/German/Dutch (x4)
106
(iii) No recognized diagnostic tests (x1) 105
(iv) No relevance to transmission/risk factors
for hepatitis E virus infection or disease
in Europe (x13)
92
(v) Duplicate results (x3) 89
Add conference proceedings (+7) 96
Add reports found in reference lists/from
correspondence with authors (+10)
106
Total 106
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Austria IgM, IgG, RNA 1 1 gt3 65 yr, male 1 N Y [113, 114]
England IgM, IgG, RNA 1 1 gt3 59 yr, male 1 Y Y (biopsy) [79]
IgM, IgG, RNA 13 8 8rgt3 Median 71 yr 46–85 yr, 85% male 13 Y Y [39]
IgM, RNA 28 16 15rgt3 Mean 61.3 yr, M:F ratio 4.6 28 Y Y [49, 54]
IgM, IgG, RNA 4 2 n.t. 61 yr, female; 62 yr, male; 82 yr, male; 19 yr, male# 3 Y N [115]
IgM, IgG, RNA 8 2 1rgt3 & 1rgt1 36–78 yr, 50% male 8 Y N [85]
IgM, IgG, RNA 2 2 2rgt3 40’s yr, male; 65 yr, male 2 Y Y [95]
IgM, RNA 1 1 gt3 58 yr, female 1 Y N [72]
IgM, RNA 1 1 gt3 61 yr, male 1 N N [116, 117]
IgM, IgG (1rIgG only) 4 n.t. n.t. 44 yr, female; 51 yr, female; 70 yr, male; 71 yr, female 4 N Y [118]
France RNA 14 14 12rgt3 28–67 yr, 11 male 14 Y Y [29]
IgM, RNA 1 1 n.t. 52 yr, male 1 Y Y (previously) [28]
IgM, IgG, RNA 1 1 gt3 72 yr, female 1 Y Y [87]
IgM, RNA 1 1 gt3 7 yr, male 1 Y Y [55]
IgG, RNA 1 1 gt3 35 yr 1 Y N [77]
IgG, RNA 3 1 n.t. 52 yr, male; 47 yr, male# ; 46 yr, female# 1 Y N [90]
IgM, RNA 2 2 n.t. 1 male, 1 female (couple) 2 Y N [88]
IgM, IgG, RNA 1 1 gt3 51 yr, female 1 Y N [119]
RNA 7$ 7 5rgt3 mean 65 yr ¡11, 5 male 7 Y Y [35]
IgG, RNA 11$ 6 n.t. mean 61 yr ¡13, 8 male 11 Y Y [120]
IgG, RNA 23$ 18 14rgt3 Mean 54.4¡16.6 yr#, 17 (74%) male 20 Y Y [53]
RNA 1$ 1 gt3 45 yr, male 1 Y Y [81]
IgM, IgG, RNA 3 3 nt 41 yr, male and his wife and child 3 Y N [90]
IgG, RNA 1 1 nt 28 yr, male 1 Y Y (therapy) [78]
IgG, RNA 1 1 gt3 41 yr, female 1 Y N [121]
Germany IgM, IgG, RNA 1 1 gt3 50 yr, male 1 N N [69]
IgG, IgM 1 n.t. n.t. n.a. 1 Y Y [91]
Hungary IgM, IgG, RNA 1 1 gt3 60 yr, male 1 Y N [70]
Italy IgM, IgG (1rIgM only) 2 n.t. n.t. 45 yr, female; 60 yr, female 2 N N [122]
Spain IgG, RNA 11 3 2rgt3, 1rgt1 Mean 55 yr# (range 28–71); 6 (67%) male 7 Y Y [86]
RNA 1 1 gt3 62 yr, male 1 Y Y [80]
The
Netherlands
IgM, IgG, RNA 2 2 2rgt3 2 Females 2 Y Y [26]
IgG, RNA 2 2 n.t. 78 yr, female; 57 yr, male 2 Y Y [123]
IgM, IgG, RNA 3 1 gt3 80 yr, female; 82 yr, female; 84 yr, male 3 Y N [124]
HEV, Hepatitis E virus; IgM/G, immunoglobulin M/G; n.t., not tested; n.a., not applicable as not covered by article; RNA, ribonucleic acid; yr, years.
* Reported risk factors and chronic comorbidity/pre-disposing factors are summarized in Appendix Table 1.
# Series included travel-related cases.















description of the infecting HEV. In fact, in 23 of the
34 reports, information on the infecting genotype was
given: of 75 HEV strains identified, 73 belonged to
gt3. On most occasions, clinical reports included
demographic information, details on symptoms and
severity of disease and the questioning of patients on
potential risk factors, including zoonotic ones. Never-
theless, it was not always clear from these case reports
how thorough and structured the questioning was.
We identified nine seroepidemiological surveys
carried out on acute non-A–C hepatitis patients
(Table 3). Within this group 4–39% were shown to
have acute hepatitis E highlighting the probable
under-detection of HEV since these patients are often
classified as patients with ‘unknown hepatitis ’. Most
studies contained information on demographics,
symptoms, and risk factor questioning. A proportion
of the identified HEV cases were confirmed by reverse-
transcriptase–polymerase chain reaction (RT–PCR),
gt3 being the most frequent genotype (Table 3).
In animals, studies assessing HEV RNA prevalence
and RNA sequence analysis are of interest. We identi-
fied 24 studies in eight European countries showing
HEV RNA in animal samples, most often in domestic
pigs (Table 4). The proportion of pigs excreting HEV
in faeces ranged between 5% and 55%. A small
number of the studies (n=7) have detected HEV
RNA from food items (n=2) [44, 45], sewage samples
of human (n=4) [19, 46–48] and animal (n=3) origin
(Table 4), and from water (n=3) [45–47].
Evidence levels 2 and 3
A total of 31 seroepidemiological surveys in humans
were identified as EL2. Two of these reports con-
tained cases also reported under EL1 [31, 49]. These
studies were carried out in different groups of people
(Tables 5 and 6) and compared groups considered at
higher risk of acquiring HEV infection either to a
group considered not be at risk or to a baseline – most
often healthy blood donors. The seroprevalence rates
in the different groups were compared, either pros-
pectively or retrospectively, to see if those considered
at higher risk have a higher seroprevalence. Care
should be taken in comparing results between sero-
surveys as different methodologies and diagnostic
tests were used, and sometimes different markers for
infection.
It is only in recent years that nationwide epidemio-
logical risk factor analyses and enhanced surveil-
lance (Table 7) have been conducted. Three studies, in
the UK [50], The Netherlands [19] and France [51]
conducted enhanced surveillance and a standardized
hypothesis-generating questionnaire was applied to
cases of autochthonous hepatitis E so that risk-factor
analysis could be undertaken. Through enhanced
surveillance it was verified that a significant pro-
portion of hepatitis E cases are indeed not travel-
associated (Table 7). Currently, only one analytical
epidemiological study, a case-control study in Ger-
many, has been carried out on hepatitis E in Europe
[52]. However, no European study has reported
identical sequences between potential source and hu-
man HEV in a logical time order.
Identification of risk factors and transmission routes
Age and sex as risk factors
There is a general trend for men and older people
being reported with HEV gt3 infection as found in
EL1 case series (Table 2), EL1 seroprevalence studies
in non-A–C hepatitis patients (Table 3) and EL2 case
series (Table 7). Acute hepatitis E patients are sig-
nificantly more likely to be older than hepatitis A
patients [53, 54]. Studies assigned to EL1–3 [32, 50,
52] have found that autochthonous hepatitis E cases
in Europe are significantly older than those who have
travelled to hyper-endemic areas. At present, only one
HEV gt3 case has been reported in a child aged <15
years, and this was an immunocompromised boy who
received infected blood by transfusion [55]. A number
of EL2 comparative seroprevalence studies (Table 6)
have also found an association between increasing age
and anti-HEV IgG prevalence. In contrast to the case
series in which about 70% of HEV cases are male
(Tables 2 and 7), being male is rarely associated with
seropositivity for anti-HEV IgG. An explanation for
the higher proportion of men and older people among
acute hepatitis E cases is not provided by any study.
However, the lack of an association in the sero-
prevalence studies conducted to date could suggest
that the dominance of male cases is due to a higher
risk for overt disease manifestations rather than for
infection.
Comorbidity as a risk factor
Increasingly, cases of acute hepatitis E are being
reported with chronic liver disease, liver cirrhosis, or
history of high alcohol consumption (Table 2). Ad-
ditionally, other comorbidities like diabetes mellitus,
compromised immune status, hypertension, obesity,
arthritis, ischaemic heart disease or previous HAV
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1996–2003 IgM, IgG, RNA 186/478 (38.9%) 11 gt3 17 Mean
68 yr (range 51–83),
13 (76%) male
Y [32]
1999–2007# IgM, IgG, RNA 42/unknown 26 gt3 40 Median age 65 yr
(35–86), 31 male
Y [31]
1998–2004# IgM, IgG, RNA 23/333 (6.3%) 16 gt3 21 Median age
67 yr (35–83), 15 male
Y [67]
France 2001–2002 IgG, RNA 46/431 (10.7%) 16 gt3 16 Mean age 52.2
(range 17–78), 13 male
Y [125]
Italy 1994–1997 IgM, IgG, RNA 22/218 (10.1%) 6 1rgt3 5 — Y [102] [126]
Spain 1989–1999 IgG, RNA 3/37 (8.1%) 3 2rgt3 2 — Y [76]
1999–2001 IgM (+WB), RNA 30/336 (8.9%) 1 gt3 1 — N [127]
The
Netherlands
2002–2004 IgM, IgG (+WB), RNA 45/1027 (4.4%) 24 16rgt3 8rgt1 16 — N [6]
2000–2002 IgM, IgG (+WB), RNA 11/209 (5.3%)$ 3 gt3 3–11 34 yr, male; 48 yr, male;
56 yr, male
N [41]
IgM/G, immunoglobulin M/G; RNA, ribonucleic acid; WB, Western blot ; yr, years.
All IgG and IgM by enzyme immunoassay unless WB also carried out which means confirmation also done by WB, all RNA detected through RT–PCR.
* Reported risk factors are summarized in Appendix Table 2.
# Overlapping patients.















infection have been reported in acute hepatitis E cases.
Even though some of these comorbidities were more
likely associated with the comparatively older age of
the patients, pre-existing diseases or behaviour affect-
ing the liver do seem to have an impact on whether
HEV infection results in clinical disease. Enhanced
surveillance in France noted that 11/47 (23%) patients
had high alcohol consumption [51], and the EL3 case-
control study in Germany [52] found that a higher but
non-significant percentage of cases than controls
(6.7% vs. 1.5%) had chronic liver disease.
Although four EL2 seroepidemiological studies
have also found that patients with comorbidities
[5, 56–58] have a higher anti-HEV IgG positivity in
comparison to the reference group a larger number
of studies found no association (Table 6). This fur-
ther supports the above-mentioned hypothesis that
comorbidities affecting the liver are mainly associated
with a higher risk of clinical disease but not infection.
Potential for zoonotic transmission by direct
animal contact
The detection of widespread HEV gt3 RNA suggests
that swine HEV is ubiquitous and epizootic in pigs
in Europe (EL1) (Table 4). Infection in pigs can be
symptomatic [59–61] but most often infections remain
clinically undetected [47, 62–65]. Close relatedness
has been found between HEV gt3 nucleotide se-
quences from pigs and wild boar and those from
human cases [6, 32, 41, 51, 60, 61, 63, 64, 66–71]. HEV
carried by a human case in the UK had 100% amino-
acid sequence homology to a UK pig HEV sequence
but no transmission link between them could be de-
fined [72]. Such sequence comparison data suggest
that in Europe, HEV carried by pigs and humans are
genetically closely related and that cross-species
transmission is occurring.
In a recent transmission study the R0 (which defines
the average total number of new infections caused by
one typical infectious animal during its entire infec-
tious period in a completely susceptible population)
for transmission of HEV in pigs was estimated to be
8.8 under experimental conditions [73]. This indicates
that HEV is able to spread efficiently between pigs
and supports the hypothesis that pigs are a reservoir
for HEV. During HEV infection, the virus is shed
mostly via faeces. Consequently, HEV RNA has been
found in the pig farm environment (Table 4) including





(where known) Prevalence (%) Ref.
England Pig Tissue and faeces Faeces : 9/40
Faeces and tissue: 2/2
26–76 [62]
Faeces — — [79]





France Pig Faeces (sewage) 5 — [75]
Germany Wild boar Serum 10/189 5.3 [128]
Hungary Pig Faeces — — [71]
Serum (piglets only) 4/18 22.2 [129]
Wild boar Faeces — — [71]
Deer Faeces — — [71]





Faeces 115/274 42 [63]
Wild boar Bile 22/88 25 [130]
The Netherlands Pig Faeces — 14–55 [131, 132] [45]
Muscle 20/39 51.3 [45]
Wild boar Faeces 1/26 3.8 [45]
Spain Pig Serum, faeces, bile, liver,
lymph nodes
— 15–50 [47, 59–61, 64,
65, 133]




Wild boar Serum 27/138 19.6 [68]
Sweden Pig Faeces 71/290 24 [134]
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Austria Yes ’ Swine farmers 39/153 (25.5%) Townspeople
(general population)









(sera from year 1983)*
144/286 (50.4%) ’ Healthy blood
donors (1983)*




France Yes# None — Healthy blood donors* 88/529 (16.6%) IgG [136]
Italy No ’ People
professionally exposed to swine
3/92 (3.3% ) General population 101/3511 (2.9%) IgG [137]
Moldova Yes ’ Healthy
swine farmers





















Spain Yes ’ People
professionally exposed to swine
19/101 (18.8%) General population
unexposed to swine
4/97 (4.1%) IgG: ELISA
confirmed by WB
[94]
Sweden No ’ Healthy
swine farmers
15/115 (13%) Non-farmers (matched) 10/108 (9.3%) IgG [8]
ELISA, Enzyme-linked immunosorbent assay; IgM/G, immunoglobulin M/G; RNA, ribonucleic acid; WB, Western blot ; yr, years.
* Risk analysis done retrospectively in each group after administering questionnaire to those tested.
# Hunting found to be an independent predictor in multivariate analysis (P=0.038). Of those that did not travel, majority lived in rural areas (P=0.07).















Table 6. Comparative seroepidemiological studies (IgG) assessing risk factors other than zoonotic exposure (Evidence level 2)
Risk factor Association found for: country [ref.] No association found for: country [ref.]
Pre-existing conditions/comorbidity
Chronic viral hepatitis patients,
HBsAg-positive, chronic liver disease
HBsAg-positivity: Albania [58]*, Greece [57]*# ; Chronic
viral hepatitis patients : Greece [57]*# ; Chronic liver
disease: Albania [58]*
HBsAg positive: Greece [98]*, Italy [141]*; chronic liver disease: Albania [140]*,
Portugal [142], England [31]*$
Antibodies against other viral hepatic
diseases (previous acute infection)
Anti-HAV-positivity: Denmark [56]*;
Anti-HBc-positivity: Greece [57]*#
Anti-HAV: Italy [101]*#, Germany [99]*·, England [49]*$ ; anti-HBc:
Greece [98]*, Albania [58]*; anti-HBV: Denmark [56]*, Greece [98]*, Italy
[141]*; HCV-infected children: Spain [97]#
Healthcare facility and parenteral exposures
Hospitalization and surgery Minor surgery and abdominal surgery: Spain [4]* Hospitalization, surgical intervention, abortion, endoscopy, dental extraction,
administration of gamma globulin: Spain [4]*; HCWs (general) : Germany
[99]*·, Spain [4]*
Healthcare workers (HCWs) HCWs working in emergency admission and surgery:
Germany [99]*·
HCWs (general) : Germany [99]*·, Spain [4]*
Haemodialysis and transfused patients Haemodialysis patients : Greece [98]*, [57]*#, Italy [96]#,
Spain [97]#
Haemodialysis patients : Spain [4]*, Sweden [139]*; Haemodialysis for >33.5
(median) months: Greece [98]*; Transfused patients : Greece [57]*#, [98]*,
Spain [4]*
Needle exposures Tattoos: Denmark [56]*; injecting drug users with HBV
exposure: Sweden [138]*
Tattoos: Denmark [56]*, Spain [4]*; injecting drug users: Denmark [56]*,
Greece [57]*#, Italy [96]#, Spain [4]*; Piercing, acupuncture, injections:
Spain [4]*
Demographics
Age Increasing prevalence with age: Denmark [56]*,
Switzerland [93]*; Albania [58]*, Spain [4]*, Italy [101]*#,
France [3]*, Sweden [139]*, England [31]*$, Albania [140]*
Greece [57]*# [98]*, Germany [99]*·
Male Spain [4]*, England [31]*$ Denmark [56]*, Greece [98]*, Italy [141]*, Italy [101]*#, Spain [4]*,
Germany [99]*·, Switzerland [93]*, France [3]*, Albania [58]*
Specific population categories
Parity Women being uni- or multiparous: Spain [4]* No. of children: Germany [99]*· ; pregnant women: Albania [140]*, Spain [143]
Migrant status Immigrants : Italy [96]# ; refugees : Greece [57]*# Immigrants: Spain [144]#, Greece [98]*
Housing >4 people in household: Italy [101]*#
Education <8 years schooling: Albania [58]* >8 years schooling: Italy [101]*# ; education: Switzerland [93]*
Occupation Airline flying personnel : Norway [100] Workers exposed to sewage: Switzerland [93]*; general occupation, years of
occupation: Germany [99]*·
Other possible exposures
Travel to endemic area Airline flying personnel : Norway [100] Travel to endemic area: Italy [141]*; travel to endemic area >5 years:
Denmark [56]*, Switzerland [93]*
* Result is from retrospective study done in a certain population group (e.g. haemodialysis patients, blood donors, prisoners, healthcare workers) rather than comparing a previously identified
risk group to a control group [either as this was (i) original study design, or (ii) in studies with risk and control groups that then looked at subgroups within these, (iii) studies which looked at risk
factors within whole HEV positive population, i.e. risk and control group merged]. Study in Denmark [56] included two different population groups: prisoners and drug-treatment-centre
patients.
# Confirmation by immunoblot/Western blot.
$ Report includes other study type of EL1 – [31] is also reported in Table 3 and [49] in Table 2.



























Table 7. Analytical studies (Evidence level 3) and case series with risk factor analysis (Evidence level 2) for hepatitis E virus (HEV) infection or hepatitis E
















State and local health
offices in Germany
Clinical manifestation and
IgM or PCR positive
45/66 14/15 Median age 46 yr (33%












IgM or rising IgG or
PCR positive
28/33 14/33 Median age 65 yr (70%













normal value plus rising IgG,
or IgM, or PCR
47/53 14/14 Mean age 56.1¡15.6 yr












Patient with acute viral
hepatitis – HEV IgM and/or
PCR positive, without travel
to endemic country 3 mos.
prior to onset of illness
19/19 13/13 Median age 50 yr
(range 25–84) 90% male
[19]
ALT, Alanine aminotransferase; ANGH, Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généaux (a national network of 96 Hepato-gastroenterology















in pig sewage [46, 74, 75], slaughterhouse sewage [76],
ditch manure [65] and a pig water trough [64].
Several EL1 case reports (Table 2) and seropre-
valance studies in non-A–C hepatitis patients (Table 3)
have alluded to pig contact (i.e. from working with
pigs to living in a rural area) as being potential risk
factors for the acquisition of HEV infection [32, 35,
39, 53, 67, 77–81]. Anti-HEV IgG seroprevalence
studies have reported that those working with pigs are
at increased risk of infection in some countries in
Europe (Austria, Denmark, Moldova, Spain), but not
in others (France, Italy, Sweden) (Table 5). In The
Netherlands, an increased risk has been found for
veterinary surgeons working with pigs when Bayesian
statistics were applied to a set of five tests, but no
increased risk was found when a validated diagnostic
protocol was followed [22]. Apart from one patient in
the case series in France being given a pet pig 8 weeks
before onset of fatigue [51, 82], remarkably, there
seems to be no correlation between pig contact and
being a hepatitis E case in the EL2 enhanced surveil-
lance studies and the German EL3 case-control study
[52]. Despite the ubiquity of HEV in a considerable
proportion of pig herds in Europe, there have been no
studies proving that contact with pigs is a risk factor
for developing hepatitis E.
HEV gt3 RNA has been isolated from wild boar in
a number of European countries (Table 4) and deer
have also been found positive for HEV gt3 in
Hungary [71]. In The Netherlands, HEV RNA was
not detected in faeces of a pet pig, horses, cows [19],
musk rats [45] or in liver tissues in dogs with hepatitis
[83], but only a few samples were analysed. Having
pets (dogs and cats) [19, 50], contact with horses
[5, 19], hunting or living in rural areas (Table 5) was
reported to be associated with HEV infection in
some EL2 studies. The German EL3 case-control
study did not find an association, indicating that fur-
ther analytical studies are needed.
Potential for foodborne zoonotic transmission
Recent studies in Spain [59, 64, 65] and Italy [63] have
shown that RNA is present in faeces, serum and liver
of pigs at the age of going to slaughter, which implies
that infected meat and organs are potentially on the
market. Two studies in Europe (EL1) have attempted
to isolate HEV from pig livers. In The Netherlands,
4/62 (6.5%) pig livers on retail sale were found posi-
tive for HEV RNA and sequencing analysis found
HEV gt3 to be closely related to HEV gt3 of pigs
(97%) and humans (93%) in The Netherlands [44].
In contrast, no pig livers were found positive in a
study conducted in 80 retail outlets in Cornwall, UK
[84]. Moreover, in The Netherlands, 20/39 (51%)
muscle samples from experimentally infected pigs,
used as proxies for pork at retail, were found positive
[45]. Positive livers contained infectious HEV as re-
vealed by the virus extracted from them being used to
successfully infect pigs. However, this success appears
to be dose-dependent as it only occurred when the
inoculum contained a high dose of virus [44].
EL1 case reports (Table 2) and seroprevalence
studies in non-A–C hepatitis patients (Table 3) have
suggested that the following food items are risk fac-
tors for the acquisition of HEV infection: pork pies
[85], liver paté [39], wild boar [77, 86], under-cooked
or raw pork [67, 72, 87, 88], home-made sausages [70],
meat (in general) [31, 67], unpasteurized milk [78],
shellfish [32, 39, 67, 85, 89, 90] and ethnic foods
[91]. Handling raw pig liver is also suggested [67].
Unpasteurized milk was associated with HEV infec-
tion in an EL2 seroepidemiological study [92]. In a
risk factor EL2 analysis using a structured question-
naire, dried sausages and uncooked shellfish (mussels,
oysters, or both) were considered risk factors associ-
ated with cases in The Netherlands and France, re-
spectively, but these studies did not use controls
[19, 51]. In the EL3 case-control study in Germany,
Wichmann et al. found that eating any offal or wild
boar was independently associated with autochthon-
ous HEV infection [52]. No significant association
was found for other food products from other animals
including shellfish.
Potential for transmission through human sewage
HEV RNA has been detected in raw human sewage in
Barcelona, Spain [19, 46–48] and in France [47]. An
EL2 study among sewage workers in the canton of
Zurich did not find a higher seroprevalence in those
exposed to waste water [93]. In the EL3 case-control
study, one of the 45 autochthonous cases had contact
with sewage, but there was no statistical difference
compared to the control group [52].
Potential for water-borne transmission
A number of EL1 case reports have described water
exposure as a possible risk factor for acquiring HEV
infection: swimming in a lake [90], through exposure
to water from a high- pressure hose, and water
sourced from a stream which ran adjacent to a free-
range pig farm [79]. In The Netherlands 2/12 (17%) of
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monthly samples of river water used for drinking
water production and recreation were found positive
for HEV RNA in two separate years [45]. By contrast,
river water samples in Spain were all found to be
negative [46].
During EL2 enhanced surveillance in The
Netherlands, HEV RNA was found in a water sample
taken from outside a patient’s home and it had an
identical sequence to that of the patient but it was
thought more likely that the patient contaminated the
water [19]. An EL2 risk factor study conducted in
France found that 15 cases (32%) drank from their
own water supply (spring or well) [51] and 1/35
samples taken from the spring was positive for HEV
RNA. An EL2 seroprevalence study found that un-
treated water consumption was a risk factor (OR 5.6,
P=0.01) for anti-HEV IgG seroprevalence confirmed
by immunoblot [94]. Conversely, the EL3 case-control
study found that drinking well water and contact with
surface was not related to HEV infection [52]. No
waterborne outbreaks have been reported in Europe
to date.
Potential for parenteral transmission
As HEV does not usually produce a chronic carrier
state, non-enteric (faecal–oral) sources were not con-
sidered as an important cause of HEV transmission.
However, cases linked to blood transfusion have now
been reported in England [95] and France [55]. In The
Netherlands, enhanced surveillance using a structured
questionnaire detected two cases of hepatitis E who
had previously received blood transfusions [19]. The
German EL3 case-control study did not identify
blood transfusion as a risk factor, which shows that
parenteral transmission does not play a significant
role in Germany (none of 46 included autochthonous
cases had received a recent blood transfusion) but
does not exclude that parenteral transmission in single
cases is possible [52]. In France, a student acquired
HEV 7 weeks after practising surgical procedures on a
pig [77].
The majority of EL2 seroepidemiological studies
looking into risk factors involving needle exposure
and many types of hospital exposure did not find a
significant difference between groups tested (Table 6).
However, haemodialysis patients in four different
studies [57, 96–98], those who had undergone minor
surgery and abdominal surgery in Spain [4], health-
care workers in emergency admission and surgery
in Germany [99] and male prisoners and drug treat-
ment patients in Denmark [56] were found to have a
higher anti-HEV IgG prevalence than the reference
group.
Potential for other transmission routes and risk factors
Some seroepidemiological studies have found other
risk groups to have higher anti-HEV antibody preva-
lence in comparison to a reference group (Table 6).
For immigrants [96], refugees [57] and probably air-
line flying personnel [100], the HEV antibodies prob-
ably did not result from HEV gt3 infection but
from gt1 infection when staying in an hyper-endemic
country. In contrast, three seroepidemiological
studies did not find an association with travel to
endemic areas (Table 6) and in one case-control study
no association was found with travel within Europe
or close contact with returning travellers [52]. The
finding of an association with a larger family size
supports the possibility of person-to-person trans-
mission [101] as has been reported for gt1 and gt2
HEV infection and is further suggested in a case series
from France [90] and a case in Italy [102]. However,
efficient person-to-person transmission is unlikely
since very few reports mention outbreaks or family
clusters of cases. In the EL2 enhanced surveillance
conducted by Borgen et al. in The Netherlands it was
specifically asked if any family members or close
contacts had signs of hepatitis in the months preced-
ing or following the disease period of the cases, but no
positive responses were elicited and a limited contact
investigation found no evidence of HEV infection
[19]. During the enhanced surveillance conducted
for the case-control study in Germany, unstructured
household investigations identified five additional
IgM-positive HEV cases in three households of auto-
chthonous cases [52], one of whom was PCR-positive.
All were asymptomatic or complained only of mild
abdominal pain or fatigue. Due to possibility of
asymptomatic infection and the wide range of the
incubation period, it was not possible to say if these
were cases due to person-to-person transmission or if
they were infected through the same source (in one
household the whole family ate wild boar, in another
they had all eaten offal).
In contrast to hyper-endemic countries [11],
there have been few studies and no reports of sexual
transmission or vertical transmission during preg-
nancy in Europe. Seroepidemiological studies have
found no association with sexual contact [4] or
pregnancy (Table 6). One HEV infection during
pregnancy occurred in Germany but without compli-
cations [52].
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DISCUSSION
This review found that there is no evidence for one
main transmission route or risk factor for HEV in-
fection or disease in Europe. Rather, multiple routes
of transmission are likely to exist. Autochthonous
HEV gt3-associated hepatitis E cases are on average
older than the general population and predominantly
male, which could be due to higher likelihood of pre-
existing comorbidity, different dietary preferences and
differences in other behaviours. Our results do indi-
cate that zoonotic transmission of HEV, either by
direct contact or food, is likely due to the following
observations : (1) the virus is highly prevalent in
domestic pigs, wild boar and to a lesser extent in deer;
(2) animal stool and tissues may contain sufficient
viral loads to be infectious ; (3) high sequence
relatedness has been found between animal and
human HEV gt3 isolates ; (4) several EL2–3 studies
have identified zoonotic risk factors. It should be
noted that not all autochthonous infections were
attributable to these factors. Other routes of trans-
mission reported in hyper-endemic countries do not
appear to be applicable to gt3 HEV infection, and our
results therefore provide further evidence for a unique
clinical and epidemiological identity of disease con-
ferred by this genotype [12]. We also found evidence
suggesting that cases of hepatitis E with underlying
diseases are at increased risk of developing clinical
manifestations or severe disease.
Current epidemiology suggests that HEV gt3 is the
predominant strain circulating in pigs in Europe and
that pigs are the natural host [20, 103]. However, the
virus can also infect a considerable proportion of
the human population, but only a minority appear to
develop symptoms [3–8]. The key to understanding
HEV transmission in Europe may lie in determining
how the virus that circulates among pigs is trans-
mitted to humans in sufficiently high doses to cause
infection or overt disease. Direct animal contact could
lead to infection associated with low-dose exposure,
thus one could argue that infection does not occur
or that the resulting infection is more likely to be
asymptomatic. Larger doses through, for example,
the consumption of heavily contaminated and in-
sufficiently cooked meat could lead to infections
that are more likely to result in clinical symptoms.
Occasional instances of HEV transmission through
sewage or consumption of contaminated water seem
possible, if a sufficiently high dose of HEV is ingested.
The failure of the virus to generate an infecting dose
when excreted by humans could be a plausible ex-
planation for the low person-to-person transmission
rates.
Evidence for foodborne zoonotic transmission of
HEV in Europe is generally weak but this is mainly
because of an insufficient number of good analytical
epidemiological studies. The only case-control study
conducted to date has suggested that, at least in
Germany, foodborne zoonotic transmission is the
main route [52]. Additional strong evidence for food-
borne transmission is available from Japan where
sequence identity between deer meat [104, 105]
and hepatitis E patients who consumed that meat, and
HEV genetic similarity between boar meat and
patient samples [106], have been found. HEV has
been shown to be viable and infectious in pigs’ liver in
the USA [107] and resistant to temperatures up to
60 xC [108]. Consequently, the role of foodborne
transmission in European countries other than
Germany should be assessed through further analyti-
cal studies. Interestingly, consumption of bivalve
molluscs [32, 39, 51, 67, 85, 89, 90] and contact with
horses [5, 19] are mentioned as possible sources of
infection in studies we reviewed. Even though anti-
HEV antibodies have been detected in many other
animal species including rats, cats, monkeys, dogs,
cattle, sheep, goats and mongooses [17, 109, 110] it is
not clear if these animals can be infected with the
HEV strains known to date, and thus their role as
possible reservoir is doubtful. Nonetheless, the poss-
ibility of another reservoir than swine transmitting
HEV to swine and humans cannot be excluded.
It is of interest that questioning of HEV patients for
enhanced surveillance studies and the case-control
study (Table 7) often found evidence for food ex-
posures whereas a number of seroepidemiological
studies conducted in healthy populations (Table 5)
found other risk factors such as animal contact. This
could be due to confounding factors such as different
dietary behaviour in rural areas where there is also
more direct animal contact than in urban settings.
Since case series and case-control studies involve
interviewing patients with a known date of onset of
hepatitis E symptoms it is also possible to enquire
about the consumption of specific food items during
the incubation period, but one should be aware of
recall problems due to length and variation of incu-
bation periods. This kind of assessment is not poss-
ible for seroepidemiological studies since the date of
HEV infection cannot be estimated. Moreover, sero-
epidemiological studies assess risk factors for infection
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whereas case series and case-control studies assess risk
factors for clinically overt disease. Risk factors for
asymptomatic HEV infection might be different from
risk factors for hepatitis E disease if, as suggested
above, the ingested dose of HEV determines whether
infection subsequently leads to overt clinical disease.
A clear limitation especially of less recent sero-
epidemiological studies is the use of poor diagnostic
kits and the results of these studies should be
interpreted with caution.
When the opportunity presents, routes of trans-
mission other than zoonotic ones may exist. The
parenteral route of transmission has been docu-
mented in people who received HEV-contaminated
blood transfusions [55, 95] and in a student practising
surgical procedures on a pig [77]. It is plausible that
patients develop disease in these instances due to the
high infectious dose inoculated. Person-to-person
spread of HEV is an uncommon event but this is not
surprising if, as proposed earlier, infection and disease
are dose-dependent [44] and require a higher infective
dose than, for example, for HAV transmission.
This is the first systematic review attempting to
define sources and transmission routes of HEV infec-
tion and disease. In conducting this review we found
that studies of higher grade evidence are lacking and
further case-control and cohort studies are required,
preferably population-based and using sensitive
diagnostic techniques such as Western blot and
RT–PCR for HEV confirmation. Standardization
of questionnaires and studies across a number of
European countries would also assist evaluation and
comparison of data. Where possible, water and food
samples of HEV patients should be analysed and
HEV strains should be genotyped to attempt to link
their infection to a source [104, 106]. Further studies
are also required to test for HEV RNA in potential
commercial food sources in Europe (e.g. pork and pig
offal, and wild boar meat) and in potential animal
reservoirs other than pigs.
The lack of evidence for one main transmission
route or risk factor, and the high possibility for mul-
tiple transmission routes, for HEV gt3 infection and
disease in Europe limits the possibility to propose
effective intervention strategies. However, proper
cooking of all pork products and prevention of cross-
contamination in the kitchen are generally accepted
guidelines that should help to prevent HEV infections.
Although the role of direct zoonotic or environmen-
tal transmission is still unclear, consideration should
still be given to improve education of occupationally
HEV-exposed people such as pig farmers and sewage
workers. Although evidence for parenteral trans-
mission is limited, it is recommended that a risk as-
sessment, including determination of the frequency
of HEV contamination, be conducted to determine
whether general screening of organs for transplan-
tation and blood products should be undertaken.
Several HEV vaccine candidates based on HEV gt1
recombinant capsid protein have been developed.
To date, two have progressed to human clinical
trials with promising preliminary results [111, 112].
Whether these vaccines provide long-term immunity
to hepatitis E still needs to be established. Even
though HEV gt1–4 are considered to belong to one
serotype, whether they have similar efficacy to protect
from HEV gt3 infections requires further study. If
licensed, the main target of the vaccine would be
those living in or travelling to HEV hyper-endemic
countries but consideration should also be given to
people living in industrialized countries with low
HEV endemicity who are at risk of a severe outcome
(e.g. patients with chronic liver disease or transplant
organ recipients).
In summary, this first systematic review of HEV in
Europe found that there is no evidence for one main
transmission route or risk factor for HEV although
evidence points towards zoonotic transmission.
Multiple routes of transmission are likely to exist, and
these need to be further defined so that specific and
appropriate preventive measures can be implemented.
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non-travel) Risk factors implicated for autochthonous cases Chronic comorbidity/pre-disposing factors Ref.
Austria 1 None identified. ’ Reported HAV in 1960s [113, 114]
England 1 Work involved being heavily splashed with water from using a
high pressure hose. Water extracted from a stream which ran
adjacent to a free-range pig farm. Pigs on this farm were HEV
positive but of non-identical sequence homology. Stream and
pond samples were negative for HEV
’ Previously consumed 40
units alcohol/week




13 2 ate shellfish, 3 ate liver paté of unspecified animal origin. 38%
dog owners
’ 4rtype 2 diabetes mellitus
’ 3rhypertension,
’ 1rhigh alcohol intake
[39]
28 5 travelled to non-endemic areas ’ 3ralcohol intake
>28 U/week
’ 3rdiagnosed with cirrhosis
(2ralcoholic, 1ridiopathic)
[49, 54]
3 All consumed meat products including pork ’ None identified [115]
8 gt1 patient was Asian and had contact with jaundiced
individual (person to person transmission likely). Of the other
7: 1 daily consumption of pork pies, 1 frequently consumed
shellfish
’ None identified [85]
2 Blood transfusion for 1 recipient. No risk factors identified for
donor
’ Donor: none
’ Recipient : B-cell lymphoma
[95]
1 Had eaten raw sausage and bacon but >3 months prior to
illness
’ None identified [72]
1 None identified ’ None identified [116, 117]
4 None identified ’ 1 previously reported viral-type illness with
jaundice and was HAV IgG-positive
[118]
France 14 2 reported contact to animals (1 with chickens and rabbits,
1 with wild birds)
’ All with organ disease and immuno-
suppressive therapy: 3rliver, 9rkidney,
2rcombined kidney and pancreas transplants
[29]
1 Consumed pork (no comment on cooking) ’ Kidney transplant recipient 2 years previously [28]





1 Blood transfusion ’ Had received chemotherapy for kidney
rhabdoid tumour
[55]
1 Consumed wild boar but 4 days before onset, surgical training
with pigs 7 weeks before onset thought most likely source
’ None identified [77]
1 Consumed uncooked shellfish during travel in Greece 1 month
before onset, Contamination in France can not be ruled out



























2 On holiday within France. Ate undercooked pig meat 4 weeks
before onset of jaundice
’ None identified [88]
1 Had travelled to HEV endemic areas (Egypt & Nepal) but gt3
isolated. Rarely ate undercooked meat
’ None identified [119]
7 2 travelled in Europe (Spain & Portugal), 1 lived on a barge,
5 lived in rural areas, 1 had pet cat
’ 5ractive drinkers (>40 g/day), 6rchronic
liver disease
[35]
11 1 travelled to Portugal month before, 1 lived in La Reunion,
1 owned dog, 1 owned cat, 1 owned dog and cat
’ 45% active drinkers [120]
20 7 travelled within Europe, 6 lived in rural areas, 12 had
household pets incl. cats, dogs and canaries. 1 had poultry
’ 7rexcessive alcohol consumption, 3rchronic
liver disease, 1 liver cirrhosis, 1 type 2 diabetes
mellitus
[53]
1 Lives in rural community and hunts partridge ’ T-cell lymphoma with chemotherapy and
stem-cell transplant
[81]
3 Man and wife consumed shellfish. Family swam in lake.
Intrafamilial transmission possible
’ None identified [89]
1 Lived in rural region, visited farm from time to time, drank
unpasteurized milk
’ Renal transplant 14 years ago, on
immunosuppressive therapy
[78]
1 Hobby gardening. Poultry near house ’ None identified [121]
Germany 1 None identified ’ None identified [69]
1 Patient Turkish – had eaten ethnic foods (maize flour, dried
nettle, sheep cheese, mushrooms in salt water) brought as a
gift by Turkish visitor
’ Serological markers for past HAV, HBV,
CMV, EBV, HSV infection. Eggs for Ascaris
lumbricoides in stools
[91]
Hungary 1 Ate pork sausages pre-prepared from house slaughtered meat
1 month previously
’ None identified [70]
Italy 2 None identified ’ None identified [122]
Spain 7 One presumptive case (IgG-positive only) ate boar meat ’ 1rIgM anti-HBc




’ Type 2 diabetes mellitus





2 Suggest that immunosuppressed long-term carriers of HEV
may be a source
’ Both liver transplant recipients [26]
2 None identified (speculate about pig meat) ’ 1rused bisphosphonate and a proton pump
inhibitor daily.




3 Had contact with domestic animals – 1 with cat, 1 with dog and
1 with goat. All drank tap water
’ None identified [124]
















Appendix Table 2. Risk factors in studies identifying autochthonous hepatitis E virus (HEV) cases among








reported) Risk factors for autochthonous cases Ref.
England & Wales 17 Comparing non-travel- to travel-associated cases : significantly more
non-travel patients lived in dense pig-holding areas or in coastal/
estuarine areas. Two cases habitual shellfish consumption
[32]
40 All were pork eaters. 21 retired, 2 unemployed. One worked as a
butcher. Seasonal variation of HEV case numbers with peaks
in spring and summer. 3 patients with previously undiagnosed
cirrhosis. HEV IgG increased with age (also did seroprevalence
study comparing risk groups)
[31]
21 One worked as butcher. One fed cat raw pigs’ liver regularly. One
had contact with pigs. All ate pork (2 uncooked), 7 shellfish. 9 kept
pets. 14 lived in urban, 16 within 10 km of coast or estuarine
settlements. 1 became anti-HAV+1 week after hospitalized.
[67]
France 16 2 had travelled to Tunisia, 3 to Spain. Not questioned for other
risk factors.
[125]
Italy 5 1 case person-to-person transmission. [102, 126]
Spain 2 1 was an injecting drug user (RNA also detected in slaughterhouse
sewage with 92–94% nucleotide homology to human strains)
[76]
1 No questioning. [127]
The
Netherlands
16 No information on questioning but ‘did not find formal proof
of zoonotic link’,1 patient anti-HAV antibody positive
[6]
3–11 Did not find clustering of cases with anti-HEV antibodies in rural
areas. Significant differences between hepatitis patients and matched
control group were found for age groups 41–60 years
[41]
HAV, Hepatitis A virus; IgG, immunoglobulinG; RNA, ribonucleic acid.
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